Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma
Open accessAbstract
The epidermal growth factor (EGF)/EGF-receptor (ErbB1-4) family is involved in the biology of multiple myeloma (MM). In particular, ErbB-specific inhibitors induce strong apoptosis of myeloma cells (MMC) in vitro. To delineate the contribution of the 10 EGF-family ligands to the pathogenesis of MM, we have assessed their expression and biological activity. Comparing Affymetrix DNA-microarray-expression-profiles of CD138-purified plasma-cells from 65 MM-patients and 7 normal individuals to those of plasmablasts and B-cells, we found 5/10 EGF-family genes to be expressed in MMC. Neuregulin-2 and neuregulin-3 were expressed by MMC only, while neuregulin-1, amphiregulin and transforming growth factor-alpha were expressed by both MMC and normal plasma-cells. Using real-time polymerase chain reaction, we found HB-EGF, amphiregulin, neuregulin-1 and epiregulin to be expressed by cells from the bone marrow-environment. Only the EGF-members able to bind heparan-sulphate proteoglycans (HSPGs) - neuregulin-1, amphiregulin, HB-EGF - promote the growth of MMC. Those ligands strongly bind MMC through HSPGs. The binding and the MMC growth activity was abrogated by heparitinase, heparin or deletion of the HS-binding domain. The number of HS-binding EGF ligand molecules bound to MMC was higher than 10(5) molecules/cell and paralleled that of syndecan-1. Syndecan-1, the main HSPG present on MM cells, likely concentrates high levels of HS-binding-EGF-ligands at the cell membrane and facilitates ErbB-activation. Altogether, our data further identify EGF-signalling as promising target for MM-therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The HS chain of SDC1 acts as a co-receptor for growth factors, promoting activation of several RTKs such as EGFR, c-MET, FGFR, and IGF1R.
“The HS chain of SDC1 has been shown to act as a co-receptor for growth factors, promoting the activation of several RTKs, such as EGFR, c-MET, FGFR, and IGF1R.29,30,31,32”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [32]
Cites
A gene atlas of the mouse and human protein-encoding transcriptomes
Su, A. I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K. A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400782101 · Cited by 3,475 · see citing works
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,313 · see citing works
Functions of Cell Surface Heparan Sulfate Proteoglycans
Bernfield, M. R., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J. M., & Zako, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.729 · Cited by 2,689 · see citing works
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633 · see citing works
Harris, R. C. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00105-2 · Cited by 786 · see citing works
Klein, B., Zhang, X., Jourdan, M., Content, J., Houssiau, F., Aarden, L. A., Piechaczyk, M., & Bataille, R. (1989) · Blood · doi:10.1182/blood.v73.2.517.517 · Cited by 763 · see citing works
Self-citationThe ErbB receptors and their role in cancer progression
Holbro, T. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00099-x · Cited by 608 · see citing works
The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy
Klerk, C. P. W., Smorenburg, S. M., Otten, H.-M., Lensing, A. W. A., Prins, M. H., Piovella, F., Prandoni, P., Bos, M. M. E. M., Richel, D. J., van Tienhoven, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.134 · Cited by 595 · see citing works
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
Citri, A. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00101-5 · Cited by 591 · see citing works
Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558 · see citing works
Self-citationSyndecans: proteoglycan regulators of cell-surface microdomains?
Couchman, J. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1257 · Cited by 430 · see citing works
Analysis of high density expression microarrays with signed-rank call algorithms
Liu, W.-M., Mei, R., Di, X., Ryder, T. B., Hubbell, E. A., Dee, S., Webster, T. A., Harrington, C. A., Ho, M.-H., Baid, J., et al. (2002) · Bioinformatics · doi:10.1093/bioinformatics/18.12.1593 · Cited by 426 · see citing works
Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases
Carraway, K. L., Weber, J. L., Unger, M. J., Ledesma, J., Yu, N., Gassmann, M., & Lai, C. (1997) · Nature · doi:10.1038/387512a0 · Cited by 394 · see citing works
Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4
Zhang, D., Sliwkowski, M. X., Mark, M. R., Frantz, G. D., Akita, R. W., Sun, Y., Hillan, K. J., Crowley, C. W., Brush, J., & Godowski, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9562 · Cited by 383 · see citing works
Identification of proteoglycans as the APRIL-specific binding partners
Ingold, K., Zumsteg, A., Tardivel, A., Huard, B., Steiner, Q., Cachero, T. G., Fang, Q., Gorelik, L., Kalled, S. L., Acha‐Orbea, H., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042309 · Cited by 365 · see citing works
Higashiyama, S., Abraham, J., & Klagsbrun, M. (1993) · The Journal of Cell Biology · doi:10.1083/jcb.122.4.933 · Cited by 362 · see citing works
A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1
Wijdenes, J., Vooijs, W. C., Clément, C., Post, J., Morard, F., Vita, N., Laurent, P., Sun, R.-X., Klein, B., & Dore, J. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.d01-1811.x · Cited by 340 · see citing works
Self-citationKarey, K. P., & Sirbasku, D. A. (1988) · PubMed · Cited by 329 · see citing works
Heparan sulfate proteoglycan as a plasma membrane carrier
Belting, M. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00031-8 · Cited by 312 · see citing works
Zhang, X., Gaillard, J., Robillard, N., Lu, Z., Gu, Z., Jourdan, M., Boiron, J.-M., Bataille, R., & Klein, B. (1994) · Blood · doi:10.1182/blood.v83.12.3654.3654 · Cited by 277 · see citing works
Self-citationDerksen, P. W. B., Keehnen, R. M. J., Evers, L. M., van Oers, M. H. J., Spaargaren, M., & Pals, S. T. (2002) · Blood · doi:10.1182/blood.v99.4.1405 · Cited by 274 · see citing works
Serum syndecan-1: a new independent prognostic marker in multiple myeloma
Seidel, C., Sundan, A., Hjorth, M., Turesson, I., Dahl, I. M. S., Abildgaard, N., Waage, A., & Børset, M. (2000) · Blood · doi:10.1182/blood.v95.2.388 · Cited by 239 · see citing works
Survival and Proliferation Factors of Normal and Malignant Plasma Cells
Klein, B., Tarte, K., Jourdan, M., Mathouk, K., Moreaux, J., Jourdan, E., Legouffe, E., de Vos, J., & Rossic, J. F. (2003) · International journal of hematology · doi:10.1007/bf02983377 · Cited by 234 · see citing works
Self-citationHeparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation
Hendriks, J., Planelles, L., Odding, J. H., Hardenberg, G., Pals, S. T., Hahne, M., Spaargaren, M., & Medema, J. P. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401647 · Cited by 216 · see citing works
Syndecan-Regulated Receptor Signaling
Rapraeger, A. C. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.149.5.995 · Cited by 197 · see citing works
Heparan sulfate proteoglycans and heparanase—partners in osteolytic tumor growth and metastasis
Sanderson, R. D., Yang, Y., Suva, L. J., & Kelly, T. J. (2004) · Matrix Biology · doi:10.1016/j.matbio.2004.08.004 · Cited by 190 · see citing works
Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines
Georgii‐Hemming, P., Wiklund, H., Ljunggren, Ö., & Nilsson, K. (1996) · Blood · doi:10.1182/blood.v88.6.2250.bloodjournal8862250 · Cited by 178 · see citing works
de Vos, J., Couderc, G., Tarte, K., Jourdan, M., Requirand, G., Delteil, M., Rossi, J., Mechti, N., & Klein, B. (2001) · Blood · doi:10.1182/blood.v98.3.771 · Cited by 177 · see citing works
Self-citationCharacterization of the Heparin-Binding Properties of IL-61
Mummery, R., & Rider, C. (2000) · Journal of Immunology · doi:10.4049/jimmunol.165.10.5671 · Cited by 170 · see citing works
Ferlin, M., Noraz, N., Hertogh, C., Brochier, J., Taylor, N. N., & Klein, B. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02364.x · Cited by 153 · see citing works
Self-citationTarte, K., Vos, J. D., Thykjær, T., Zhan, F., Fiol, G., Costes, V., Reme, T. X., Legouffe, É., Rossi, J., Shaughnessy, J. D., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1113.h81602001113_1113_1122 · Cited by 150 · see citing works
Self-citationParia, B. C., Elenius, K., Klagsbrun, M., & Dey, S. K. (1999) · Development · doi:10.1242/dev.126.9.1997 · Cited by 135 · see citing works
Bayer‐Garner, I. B., Sanderson, R. D., Dhodapkar, M. V., Owens, R., & Wilson, C. S. (2001) · Modern Pathology · doi:10.1038/modpathol.3880435 · Cited by 131 · see citing works
Goger, B., Halden, Y., Rek, A., Mösl, R., Pye, D. A., Gallagher, J. T., & Kungl, A. J. (2002) · Biochemistry · doi:10.1021/bi011944j · Cited by 131 · see citing works
ARIA can be released from extracellular matrix through cleavage of a heparin-binding domain.
Loeb, J. A., & Fischbach, G. D. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.130.1.127 · Cited by 130 · see citing works
Børset, M., Hjertner, Ø., Yaccoby, S., Epstein, J., & Sanderson, R. D. (2000) · Blood · doi:10.1182/blood.v96.7.2528 · Cited by 121 · see citing works
Management of multiple myeloma: a systematic review and critical appraisal of published studies
Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01077-5 · Cited by 113 · see citing works
Jelinek, D. F., Witzig, T. E., & Arendt, B. K. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.487 · Cited by 110 · see citing works
Seidel, C., Børset, M., Hjertner, Ø., Cao, D., Abildgaard, N., Hjorth‐Hansen, H., Sanderson, R. D., Waage, A., & Sundan, A. (2000) · Blood · doi:10.1182/blood.v96.9.3139 · Cited by 106 · see citing works
Mahtouk, K., Hose, D., Reme, T. X., Vos, J. D., Jourdan, M., Moreaux, J., Fiol, G., Raab, M. S., Jourdan, É., Grau, V., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208536 · Cited by 105 · see citing works
Self-citationDhodapkar, M. V., Kelly, T. J., Theus, A. M., Athota, A. B., Barlogie, B., & Sanderson, R. D. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.3893203.x · Cited by 100 · see citing works
Costes, V. (1999) · Human Pathology · doi:10.1016/s0046-8177(99)90160-0 · Cited by 89 · see citing works
Johnson, G. R., & Wong, L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47137-2 · Cited by 78 · see citing works
Mahtouk, K., Jourdan, M., Vos, J. D., Hertogh, C., Fiol, G., Jourdan, É., Rossi, J., & Klein, B. (2003) · Blood · doi:10.1182/blood-2003-05-1510 · Cited by 76 · see citing works
Self-citationWang, Y. D., Vos, J. D., Jourdan, M., Couderc, G., Lu, Z., Rossi, J., & Klein, B. (2002) · Oncogene · doi:10.1038/sj.onc.1205355 · Cited by 65 · see citing works
Self-citationA gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma
Rebouissou, C., Wijdenes, J., Autissier, P., Tarte, K., Costes, V., Liautard, J., Rossi, J., Brochier, J., & Klein, B. (1998) · Blood · doi:10.1182/blood.v91.12.4727 · Cited by 63 · see citing works
Self-citationCD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells
van Driel, M., Günthert, U., van Kessel, A., Joling, P., Stauder, R., Lokhorst, H. M., & Bloem, A. C. (2002) · Leukemia · doi:10.1038/sj.leu.2402336 · Cited by 61 · see citing works
Tarte, K., Lu, Z., Fiol, G., Legouffe, É., Rossi, J., & Klein, B. (1997) · Blood · doi:10.1182/blood.v90.9.3482 · Cited by 39 · see citing works
Self-citationNon-anti-coagulant heparins: A promising approach for prevention of tumor metastasis (Review)
Kragh, M., & Loechel, F. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.4.1159 · Cited by 37 · see citing works
Large scale and clinical grade purification of syndecan-1+ malignant plasma cells
Sun, R.-X., Lu, Z., Wijdenes, J., Brochier, J., Hertog, C., Rossi, J., & Klein, B. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00056-2 · Cited by 28 · see citing works
Self-citationActivation Molecules on Human Myeloma Cells
Klein, B., Li, X. Y., Lu, Z., Jourdan, M., Tarte, K., Brochier, J., Claret, E. J., Wijdenes, J., & Rossi, J. (1999) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-60162-0_41 · Cited by 9 · see citing works
Self-citation
Flagged first, then by citations
1 of the 52 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Berasain, C., & Avila, M. A. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.01.005 · Cited by 304 · see citing works
Functional selectivity of EGF family peptide growth factors: Implications for cancer
Wilson, K. J., Gilmore, J. L., Foley, J., Lemmon, M. A., & Riese, D. J. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.008 · Cited by 286 · see citing works
Syndecans – key regulators of cell signaling and biological functions
Afratis, N. A., Nikitovic, D., Multhaupt, H. A. B., Theocharis, A. D., Couchman, J., & Karamanos, N. K. (2016) · FEBS Journal · doi:10.1111/febs.13940 · Cited by 283 · see citing works
Jourdan, M., Caraux, A., Vos, J. D., Fiol, G., Larroque, M., Cognot, C., Bret, C., Duperray, C., Hose, D., & Klein, B. (2009) · Blood · doi:10.1182/blood-2009-07-235960 · Cited by 247 · see citing works
Self-citationIkeda, H., Hideshima, T., Fulciniti, M., Lutz, R. J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2867 · Cited by 203 · see citing works
Sprynski, A. C., Hose, D., Caillot, L., Reme, T. X., Shaughnessy, J. D., Barlogie, B., Seckinger, A., Moreaux, J., Hundemer, M., Jourdan, M., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170464 · Cited by 173 · see citing works
Self-citationCD138 mediates selection of mature plasma cells by regulating their survival
McCarron, M. J., Park, P. W., & Fooksman, D. (2017) · Blood · doi:10.1182/blood-2017-01-761643 · Cited by 150 · see citing works
Mahtouk, K., Hose, D., Raynaud, P., Hundemer, M., Jourdan, M., Jourdan, É., Pantesco, V., Baudard, M., Vos, J. D., Larroque, M., et al. (2007) · Blood · doi:10.1182/blood-2006-08-043232 · Cited by 137 · see citing works
Self-citationThe syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
Yang, Y., MacLeod, V., Dai, Y., Khotskaya-Sample, Y., Shriver, Z. H., Venkataraman, G., Sasisekharan, R., Naggi, A., Torri, G., Casu, B., et al. (2007) · Blood · doi:10.1182/blood-2007-04-082495 · Cited by 133 · see citing works
Moreaux, J., Sprynski, A. C., Dillon, S. R., Mahtouk, K., Jourdan, M., Ythier, A., Moine, P., Robert, N., Jourdan, É., Rossi, J. F., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01262.x · Cited by 119 · see citing works
Self-citationThe molecular characterization and clinical management of multiple myeloma in the post-genome era
Zhou, Y., Barlogie, B., & Shaughnessy, J. D. (2009) · Leukemia · doi:10.1038/leu.2009.160 · Cited by 104 · see citing works
Syndecan-1 Is Required for Robust Growth, Vascularization, and Metastasis of Myeloma Tumors in Vivo
Khotskaya, Y. B., Dai, Y., Ritchie, J. P., MacLeod, V., Yang, Y., Zinn, K. R., & Sanderson, R. D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.018473 · Cited by 102 · see citing works
Syndecans as Modulators and Potential Pharmacological Targets in Cancer Progression
Barbouri, D., Afratis, N. A., Gialeli, C., Vynios, D. H., Theocharis, A. D., & Karamanos, N. K. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00004 · Cited by 93 · see citing works
Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins
Ren, Z., van Andel, H., de Lau, W., Hartholt, R. B., Maurice, M. M., Clevers, H. C., Kersten, M. J., Spaargaren, M., & Pals, S. T. (2017) · Blood · doi:10.1182/blood-2017-07-797050 · Cited by 87 · see citing works
Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination
Akhmetzyanova, I., McCarron, M. J., Parekh, S. S., Chesi, M., Bergsagel, P. L., & Fooksman, D. (2019) · Leukemia · doi:10.1038/s41375-019-0519-4 · Cited by 83 · see citing works
Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma
Reijmers, R. M., Groen, R. W. J., Rozemuller, H., Kuil, A., de Haan-Kramer, A., Csikós, T., Martens, A. C., Spaargaren, M., & Pals, S. T. (2009) · Blood · doi:10.1182/blood-2009-02-204396 · Cited by 79 · see citing works
Heparan Sulfate Proteoglycan Modulation of Wnt5A Signal Transduction in Metastatic Melanoma Cells
O’Connell, M. P., Fiori, J. L., Kershner, E. K., Frank, B. P., Indig, F. E., Taub, D. D., Hoek, K. S., & Weeraratna, A. T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.028498 · Cited by 79 · see citing works
Seckinger, A., Meißner, T., Moreaux, J., Goldschmidt, H., Fuhler, G. M., Benner, A., Hundemer, M., Reme, T. X., Shaughnessy, J. D., Barlogie, B., et al. (2009) · Oncogene · doi:10.1038/onc.2009.257 · Cited by 79 · see citing works
Self-citationBret, C., Hose, D., Reme, T. X., Sprynski, A. C., Mahtouk, K., Schved, J., Quittet, P., Rossi, J., Goldschmidt, H., & Klein, B. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07633.x · Cited by 73 · see citing works
Self-citationAPRIL is overexpressed in cancer: link with tumor progression
Moreaux, J., Veyrune, J., Vos, J. D., & Klein, B. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-83 · Cited by 71 · see citing works
Self-citationOdintsova, E., van Niel, G., Conjeaud, H., Raposo, G., Iwamoto, R., Mekada, E., & Berditchevski, F. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.439380 · Cited by 66 · see citing works
Mahtouk, K., Moreaux, J., Hose, D., Reme, T. X., Meißner, T., Jourdan, M., Rossi, J. F., Pals, S. T., Goldschmidt, H., & Klein, B. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-198 · Cited by 62 · see citing works
Self-citationBone marrow microenvironment in myelomagenesis: its potential role in early diagnosis
Balakumaran, A., Robey, P. G., Fedarko, N. S., & Landgren, O. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.31 · Cited by 61 · see citing works
Syndecans play dual roles as cell adhesion receptors and docking receptors
Kwon, M.-J., Jang, B., Yi, J. Y., Han, I., & Oh, E. S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.05.037 · Cited by 60 · see citing works
Roles of glycosaminoglycans as regulators of ligand/receptor complexes
Smock, R. G., & Meijers, R. (2018) · Open Biology · doi:10.1098/rsob.180026 · Cited by 54 · see citing works
Fernández‐Vega, I., García‐Suárez, O., García, B., Crespo, A., Astudillo, A., & Quirós, L. M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1724-9 · Cited by 56 · see citing works
Reijmers, R. M., Spaargaren, M., & Pals, S. T. (2013) · FEBS Journal · doi:10.1111/febs.12180 · Cited by 55 · see citing works
Shimada, K., Anai, S., Fujii, T., Tanaka, N., Fujimoto, K., & Konishi, N. (2013) · The Journal of Pathology · doi:10.1002/path.4271 · Cited by 54 · see citing works
Differential transcriptome and development of human peripheral plasma cell subsets
Garimalla, S., Nguyen, D. C., Halliley, J. L., Tipton, C. M., Rosenberg, A. F., Fucile, C., Saney, C. L., Kyu, S. Y., Kaminski, D. A., Yu, Q., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126732 · Cited by 52 · see citing works
Targeting NF‐κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth
Jourdan, M., Moreaux, J., Vos, J. D., Hose, D., Mahtouk, K., Abouladzé, M., Robert, N., Baudard, M., Reme, T. X., Romanelli, A., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06629.x · Cited by 54 · see citing works
Self-citationGarcía-Gómez, A., Rivas, J. D. L., Ocio, E. M., Dı́az-Rodrı́guez, E., Montero, J. C., Martín, M., Blanco, J. F., Sanchez-Guijo, F. M., Pandiella, A., Miguel, J. F. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2058 · Cited by 53 · see citing works
Role of syndecan‐1 (CD138) in cell survival of human urothelial carcinoma
Shimada, K., Nakamura, M., Velasco, M. A. D., Tanaka, M., Ouji, Y., Miyake, M., Fujimoto, K., Hirao, K., & Konishi, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01379.x · Cited by 53 · see citing works
Ren, Z., Lantermans, H. C., Kuil, A., Kraan, W., Arenzana‐Seisdedos, F., Kersten, M. J., Spaargaren, M., & Pals, S. T. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01031-3 · Cited by 52 · see citing works
Failure to launch: aberrant cumulus gene expression during oocyte in vitro maturation
Brown, H. M., Dunning, K. R., Sutton‐McDowall, M. L., Gilchrist, R. B., Thompson, J. G., & Russell, D. L. (2016) · Reproduction · doi:10.1530/rep-16-0426 · Cited by 50 · see citing works
Reme, T. X., Hose, D., Vos, J. D., Vassal, A., Poulain, P.-O., Pantesco, V., Goldschmidt, H., & Klein, B. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-16 · Cited by 48 · see citing works
Self-citationHeparosan‐Derived Heparan Sulfate/Heparin‐Like Compounds: One Kind of Potential Therapeutic Agents
Li, P., Sheng, J., Liu, Y., Li, J., Liu, J., & Wang, F. (2012) · Medicinal Research Reviews · doi:10.1002/med.21263 · Cited by 47 · see citing works
Syndecan‐1, a new target molecule involved in progression of androgen‐independent prostate cancer
Shimada, K., Nakamura, M., Velasco, M. A. D., Tanaka, M., Ouji, Y., & Konishi, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01174.x · Cited by 46 · see citing works
Moreaux, J., Hose, D., Jourdan, M., Reme, T. X., Hundemer, M., Moos, M., Robert, N., Moine, P., Vos, J. D., Goldschmidt, H., et al. (2007) · Haematologica · doi:10.3324/haematol.10574 · Cited by 46 · see citing works
Self-citationFuhler, G. M., Baanstra, M., Chesik, D., Somasundaram, R., Seckinger, A., Hose, D., Peppelenbosch, M. P., & Bos, N. A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.03.013 · Cited by 44 · see citing works
Self-citationVinante, F., & Rigo, A. (2013) · Toxins · doi:10.3390/toxins5061180 · Cited by 43 · see citing works
Klein, B., Seckinger, A., Moehler, T. M., & Hose, D. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_3 · Cited by 38 · see citing works
Self-citationCirculating Heparan Sulfate Proteoglycans as Biomarkers in Health and Disease
Lepedda, A. J., Nieddu, G., Piperigkou, Z., Kyriakopoulou, K., Karamanos, N. K., & Formato, M. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1725063 · Cited by 37 · see citing works
Syndecan-4 regulates extravillous trophoblast migration by coordinating protein kinase C activation
Jeyarajah, M. J., Bhattad, G. J., Kops, B. F., & Renaud, S. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-46599-6 · Cited by 35 · see citing works
Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential
Ceci, C., Lacal, P. M., & Graziani, G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108106 · Cited by 35 · see citing works
Relationship between SDC1 and cadherin signalling activation in cancer
Liao, S., Liu, C., Zhu, G.-Y., Wang, K., Yang, Y. C., & Wang, C. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152756 · Cited by 34 · see citing works
Unraveling the mysteries of plasma cells
Schuh, W., Mielenz, D., & Jäck, H. (2020) · Advances in immunology · doi:10.1016/bs.ai.2020.01.002 · Cited by 34 · see citing works
Dunning, K. R., Watson, L. N., Zhang, V. J., Brown, H. M., Kaczmarek, A., Robker, R. L., & Russell, D. L. (2015) · Biology of Reproduction · doi:10.1095/biolreprod.114.127274 · Cited by 34 · see citing works
Ren, Z., Spaargaren, M., & Pals, S. T. (2021) · Blood · doi:10.1182/blood.2020008188 · Cited by 31 · see citing works
Condomines, M., Hose, D., Reme, T. X., Requirand, G., Hundemer, M., Schoenhals, M. J., Goldschmidt, H., & Klein, B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803298 · Cited by 28 · see citing works
Self-citationNew Negative Feedback Regulators of Egfr Signaling in Drosophila
Butchar, J. P., Cain, D. M., Manivannan, S., McCue, A. D., Bonanno, L. N., Halula, S. E., Truesdell, S. L., Austin, C. L., Jacobsen, T. L., & Simcox, A. A. (2012) · Genetics · doi:10.1534/genetics.112.141093 · Cited by 26 · see citing works
Development of target‐specific treatments in multiple myeloma
Chanan-Khan, A. A., Borrello, I., Lee, K. P., & Reece, D. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08262.x · Cited by 24 · see citing works
Crespo, A., García‐Suárez, O., Fernández‐Vega, I., Solís-Hernández, M. P., García, B., Castañón, S., & Quirós, L. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4597-x · Cited by 23 · see citing works
Targeted therapy for multiple myeloma: an overview on CD138-based strategies
Riccardi, F., Tangredi, C., Bo, M. D., & Toffoli, G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1370854 · Cited by 22 · see citing works
Mahtouk, K., Hose, D., Vos, J. D., Moreaux, J., Jourdan, M., Rossi, J. F., Reme, T. X., Goldschmidt, H., & Klein, B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1758 · Cited by 22 · see citing works
Self-citationAssembling custom side chains on proteoglycans to interrogate their function in living cells
Wang, W., Han, N., Xu, Y., Zhao, Y., Shi, L., Filmus, J., & Li, F. (2020) · Nature Communications · doi:10.1038/s41467-020-19765-y · Cited by 21 · see citing works
Kassambara, A., Hose, D., Moreaux, J., Reme, T. X., Torrent, J., Rossi, J. F., Goldschmidt, H., & Klein, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042161 · Cited by 21 · see citing works
Self-citationInsights on ErbB glycosylation – contributions to precision oncology
Duarte, H. O., Reis, C. A., & Gomes, J. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.02.003 · Cited by 21 · see citing works
Glycans in Diseases and Therapeutics
Pavão, M. S. G. (2011) · Springer eBooks · doi:10.1007/978-3-642-16833-8 · Cited by 22 · see citing works
Liu, L., & Akkoyunlu, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101053 · Cited by 18 · see citing works
N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma
Chen, J., Fang, M., Chen, X., Yi, C., Ji, J., Cheng, C., Wang, M., Gu, X., Sun, Q.-S., & Gao, C. (2017) · BMC Cancer · doi:10.1186/s12885-017-3891-3 · Cited by 18 · see citing works
The Glycome of Normal and Malignant Plasma Cells
Moehler, T. M., Seckinger, A., Hose, D., Andrulis, M., Moreaux, J., Hielscher, T., Willhauck-Fleckenstein, M., Merling, A., Bertsch, U., Jauch, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083719 · Cited by 17 · see citing works
Self-citationThe Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment
Jurczyszyn, A. J., Zebzda, A., Czepiel, J., Gdula‐Argasińska, J., Perucki, W. H., Skotnicki, A. B., & Majka, M. (2015) · Journal of Cancer · doi:10.7150/jca.10873 · Cited by 15 · see citing works
Amphiregulin in infectious diseases: Role, mechanism, and potential therapeutic targets
Hsu, C., Faisal, A., Porras, S., Grillo, I. J. P., Mustafa, M. A., Saadh, M. J., Adil, M., & Zainab, H. A. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106463 · Cited by 12 · see citing works
Targeted Therapies in Adult B-Cell Malignancies
Rossi, J. (2015) · BioMed Research International · doi:10.1155/2015/217593 · Cited by 12 · see citing works
Self-citationExocrine Gland Morphogenesis: Insights into the Role of Amphiregulin from Development to Disease
Sisto, M., Lorusso, L., Ingravallo, G., & Lisi, S. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0478-2 · Cited by 11 · see citing works
Tatsumi, Y., Miyake, M., Shimada, K., Fujii, T., Hori, S., Morizawa, Y., Nakai, Y., Anai, S., Tanaka, N., Konishi, N., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113789 · Cited by 11 · see citing works
Soureas, K., Papadimitriou, M., Malandrakis, P., Παπανώτα, Α.-Μ., Adamopoulos, P. G., Ntanasis‐Stathopoulos, I., Liacos, C., Gavriatopoulou, M., Sideris, D. C., Kastritis, E., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19332 · Cited by 8 · see citing works
Gm40600 suppressed SP 2/0 isograft tumor by reducing Blimp1 and Xbp1 proteins
Fang, Y., Xu, R., Zhai, B., Hou, C., Ma, N., Wang, L., Han, G., Jiang, Z., & Wang, R. (2019) · BMC Cancer · doi:10.1186/s12885-019-5848-1 · Cited by 8 · see citing works
Niche-modulated and niche-modulating genes in bone marrow cells
Cohen, Y., Garach‐Jehoshua, O., Bar‐Chaim, A., & Kornberg, A. (2012) · Blood Cancer Journal · doi:10.1038/bcj.2012.42 · Cited by 7 · see citing works
Theardy, M. S., Takeda, M., Sorokin, A., Chen, S., Yang, Z., Wang, X., Kanikarla, P., Coker, O., Nguyen, P., Wei, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102253 · Cited by 6 · see citing works
The MUC1 Cytoplasmic Tail and Tandem Repeat Domains Contribute to Mammary Oncogenesis in FVB Mice
Hattrup, C. L., Bradley, J. M., Kotlarczyk, K. L., Madsen, C. S., Hentz, J. G., Marler, R. J., & Gendler, S. J. (2008) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s655 · Cited by 6 · see citing works
Baert, L., Manfroi, B., Quintero, M., Chavarria, O., Barbon, P.-V., Clement, E., Zeller, A., Kuppevelt, T. H. V., Stürm, N., Moreaux, J., et al. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.05.005 · Cited by 6 · see citing works
Self-citationMultiple myeloma (pathogenesis, clinical features, diagnosis, differential diagnosis). Part I
Бессмельцев, С. С. (2013) · Clinical oncohematology · doi:10.21320/2500-2139-2013-6-3-237-257 · Cited by 6 · see citing works
Loc108167440 suppressed myeloma cell growth by P53-mediated apoptosis
Zhai, B., Hou, C., Xu, R., Fang, Y., He, X., Chen, G., Wang, X., Ma, N., Han, G., & Wang, R. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1590572 · Cited by 6 · see citing works
Maille, E., Levallet, J., Dubois, F., Antoine, M., Danel, C. J., Créveuil, C., Mazières, J., Margery, J., Greillier, L., Gounant, V., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33997 · Cited by 4 · see citing works
Engineering antibodies with cancer‐associated binding sites
Tian, Y., Pan, Y., Zhang, Y., Wang, F., & Wang, Z. (2024) · BMEMat · doi:10.1002/bmm2.12134 · Cited by 3 · see citing works
B cell antigens: A key to optimizing CAR-T cell therapy
Khodke, P., Hasurkar, D., Upadhyay, A., Shedge, A., Sippy, R., & Kumbhar, B. V. (2025) · International Reviews of Immunology · doi:10.1080/08830185.2025.2515839 · Cited by 3 · see citing works
Ikeda, H., Hideshima, T., Lutz, R., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., Perrone, G., et al. (2008) · Nature Precedings · doi:10.1038/npre.2008.2374.1 · Cited by 2 · see citing works
Sioud, M., & Olberg, A. (2023) · Cancers · doi:10.3390/cancers15071934 · Cited by 1 · see citing works
Heparan Sulfate Proteoglycans in Cancer Therapy
Gassar, E. S., Ibrahim, S., & Götte, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16833-8_6 · Cited by 1 · see citing works
Circulating Proteoglycans/Glycosaminoglycans as Cancer Biomarkers
Lepedda, A. J., Nieddu, G., Karamanos, N. K., & Formato, M. (2022) · Biology of extracellular matrix · doi:10.1007/978-3-030-99708-3_6 · Cited by 1 · see citing works
Zhou, Y., Shen, J., Jin, K., Lin, C., Hong, Z., & Deng, S. (2020) · doi:10.21203/rs.3.rs-97494/v1 · Cited by 1 · see citing works
Growth Factors in Multiple Myeloma
Moreaux, J., Bret, C., Mahtouk, K., Sprynski, A. C., Hose, D., & Klein, B. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4666-8_4
Self-citationChung, T., & Chng, W. J. (2012) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.18
Lacombe, M., Ferrer, L., Supiot, S., Bardiès, M., Davodeau, F., Faivre-Chauvet, A., Baumgartner, P., Wijdenes, J., Barbet, J., Guillaume, T., et al. (2012) · Médecine Nucléaire · doi:10.1016/j.mednuc.2011.12.002
Hepatocyte growth factor, c-Met and syndecan-1 in multiple myeloma
Wader, K. F. (2011) · NORA - Norwegian Open Research Archives
Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma
Leleu, X. P., & Anderson, K. C. (2007) · CRC Press eBooks · doi:10.3109/9781420045116-14
The biology of ADAMs in renal disease
Melenhorst, W. B. W. H. (2009) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Mahtouk, K., Vos, J. D., Moreaux, J., Jourdan, M., Baudard, M., Rossi, J. F., Reme, T. X., & Klein, B. (2016)
Self-citationTrujillo, D. L., Jarousse, N., & Coscoy, L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/514588
Cases, P. V. I. (2001) · Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona)
Liu, L., & Akkoyunlu, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.11.443667
Characterization of Expression and Function of Heparan Sulfate on Murine B Cells
Trujillo, D. L. (2012) · eScholarship (California Digital Library)
Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma
Leleu, X. P., & Anderson, K. C. (2007) · Translational medicine series · doi:10.3109/9781420045116.011
Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R. J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., et al. (2023) · doi:10.1158/1078-0432.c.6517504
Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R. J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., et al. (2023) · doi:10.1158/1078-0432.c.6517504.v1
Takeda, M., Theardy, M. S., Sorokin, A. V., Coker, O., Marie, P. K., Chen, S., Yang, Z., Nguyen, P. T.-M., Wei, Y., Yao, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.06.606865
Rôle du système IGF-1/insuline dans le Myélome Multiple
Sprynski, A. C. (2009) · HAL
Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment
Raab, M. S., & Anderson, K. C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_3
- Authors
- Mahtouk, K., Cremer, F. W., Rème, T., Jourdan, M., Baudard, M., Moreaux, J., Requirand, G., Fiol, G., De Vos, J., Moos, M., Quittet, P., Goldschmidt, H., Rossi, J.-F., Hose, D., & Klein, B.
- Affiliations
- Inserm (FR)
- University Hospital Heidelberg (DE)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Corresponding author
- Klein, B
- Venue
- Oncogene
- Published
- 2006-05-29
- Volume
- 25
- Issue
- 54
- Pages
- 7180-7191
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC2396200
- OpenAlex
- W1983381655
- Cited by
- 105
- References
- 52
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 4 · 2019: 7 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 6 · 2012: 9
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- multiple myeloma, heparan sulfate proteoglycans, EGF family ligands, ErbB receptors, neuregulin-1, amphiregulin, HB-EGF, epiregulin, syndecan-1, myeloma cell growth, EGF signaling, heparitinase, heparin, plasma cells, bone marrow microenvironment, EGFR inhibitors
- MeSH terms
- B-Lymphocytes, Epidermal Growth Factor, Flow Cytometry, Hematopoietic Stem Cells, Humans, Ligands, Middle Aged, Multiple Myeloma, Plasma Cells, RNA, Messenger, Signal Transduction, Gene Expression, Heparan Sulfate Proteoglycans, Reverse Transcriptase Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Cell Proliferation, Syndecan-1, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
